"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Descriptor ID |
D000998
|
MeSH Number(s) |
D27.505.954.122.388
|
Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 3 | 6 | 9 |
1996 | 5 | 3 | 8 |
1997 | 5 | 3 | 8 |
1998 | 2 | 4 | 6 |
1999 | 6 | 5 | 11 |
2000 | 4 | 9 | 13 |
2001 | 5 | 3 | 8 |
2002 | 4 | 7 | 11 |
2003 | 12 | 10 | 22 |
2004 | 15 | 6 | 21 |
2005 | 12 | 8 | 20 |
2006 | 5 | 14 | 19 |
2007 | 17 | 6 | 23 |
2008 | 11 | 6 | 17 |
2009 | 10 | 14 | 24 |
2010 | 15 | 10 | 25 |
2011 | 13 | 13 | 26 |
2012 | 14 | 12 | 26 |
2013 | 16 | 10 | 26 |
2014 | 21 | 9 | 30 |
2015 | 27 | 12 | 39 |
2016 | 22 | 16 | 38 |
2017 | 29 | 15 | 44 |
2018 | 30 | 9 | 39 |
2019 | 23 | 13 | 36 |
2020 | 28 | 24 | 52 |
2021 | 22 | 21 | 43 |
2022 | 8 | 44 | 52 |
2023 | 4 | 28 | 32 |
2024 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma. Lancet. 2024 Apr 06; 403(10434):1372-1373.
-
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis. J Exp Clin Cancer Res. 2024 Mar 05; 43(1):68.
-
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. J Pediatric Infect Dis Soc. 2024 Feb 28; 13(Supplement_1):S14-S21.
-
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy. Drug Saf. 2024 Apr; 47(4):321-332.
-
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
-
Antiviral fibrils of self-assembled peptides with tunable compositions. Nat Commun. 2024 Feb 07; 15(1):1142.
-
Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection. Nat Commun. 2024 Jan 02; 15(1):109.
-
Oseltamivir May or May Not Reduce Hospitalizations. JAMA Intern Med. 2024 Jan 01; 184(1):116.
-
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Dec 22; 72(51):1365-1370.
-
Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection. Influenza Other Respir Viruses. 2023 Dec; 17(12):e13231.